Soybean seeds expressing transgenic proteins represent a novel, sustainable platform technology which overcomes some of the current limitations for producing recombinant proteins useful as immunotherapeutics. Advantages include low cost of glycoslyated protein production, greenhouse containment, highest protein/biomass ratio, marketable formulations which require no purification from soy, safety, accurate dosing, low cost of protein purification, low-tech sustainability of product lines, reduced risk of contamination, ease of scalability, minimal waste produced, as well as being a green technology. We have successfully expressed a variety of subunit protein antigens, and potential immunomodulatory proteins in transgenic soybean seeds, and are evaluating their usefulness as vaccines and therapeutics. The flexibility of long-term storage of transgenic seeds or powder in the absence of a cold chain and without degradation allows protein expression to occur years in advance of its therapeutic use. Purification of a transgenic protein is simplified by the limited number of soy proteins present in seeds. Furthermore, transgenic protein expression levels of approximately 13 grams per liter of soy powder and 22 kilograms per greenhouse acre represent the highest protein/biomass ratio for the industry, and contribute to low production costs. As protein expression technologies expand and evolve, transgenic soybean seeds represent an emerging technology with significant advantages.
- Copyright © 2011 by The American Association of Immunologists, Inc.